vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $31.4M, roughly 1.4× Ponce Financial Group, Inc.). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -23.3%, a 59.6% gap on every dollar of revenue. On growth, Ponce Financial Group, Inc. posted the faster year-over-year revenue change (37.6% vs 7.0%). Over the past eight quarters, Ponce Financial Group, Inc.'s revenue compounded faster (23.7% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.

AMRN vs PDLB — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.4× larger
AMRN
$45.1M
$31.4M
PDLB
Growing faster (revenue YoY)
PDLB
PDLB
+30.6% gap
PDLB
37.6%
7.0%
AMRN
Higher net margin
PDLB
PDLB
59.6% more per $
PDLB
36.3%
-23.3%
AMRN
Faster 2-yr revenue CAGR
PDLB
PDLB
Annualised
PDLB
23.7%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
PDLB
PDLB
Revenue
$45.1M
$31.4M
Net Profit
$-10.5M
$10.1M
Gross Margin
Operating Margin
35.5%
43.6%
Net Margin
-23.3%
36.3%
Revenue YoY
7.0%
37.6%
Net Profit YoY
33.0%
245.6%
EPS (diluted)
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
PDLB
PDLB
Q1 26
$45.1M
Q4 25
$49.2M
$31.4M
Q3 25
$49.7M
$26.7M
Q2 25
$72.7M
$26.5M
Q1 25
$42.0M
$24.6M
Q4 24
$62.3M
$22.8M
Q3 24
$42.3M
$20.2M
Q2 24
$67.5M
$20.2M
Net Profit
AMRN
AMRN
PDLB
PDLB
Q1 26
$-10.5M
Q4 25
$-1.2M
$10.1M
Q3 25
$-7.7M
$6.5M
Q2 25
$-14.1M
$6.1M
Q1 25
$-15.7M
$6.0M
Q4 24
$-48.6M
$2.9M
Q3 24
$-25.1M
$2.4M
Q2 24
$1.5M
$3.2M
Gross Margin
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
Q3 24
38.5%
Q2 24
63.4%
Operating Margin
AMRN
AMRN
PDLB
PDLB
Q1 26
35.5%
Q4 25
-12.9%
43.6%
Q3 25
-22.4%
32.8%
Q2 25
-22.0%
30.2%
Q1 25
-39.9%
32.5%
Q4 24
-84.3%
19.6%
Q3 24
-59.5%
15.2%
Q2 24
-0.8%
21.8%
Net Margin
AMRN
AMRN
PDLB
PDLB
Q1 26
-23.3%
Q4 25
-2.5%
36.3%
Q3 25
-15.6%
24.3%
Q2 25
-19.4%
23.0%
Q1 25
-37.4%
24.2%
Q4 24
-78.0%
14.1%
Q3 24
-59.4%
12.1%
Q2 24
2.3%
15.8%
EPS (diluted)
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
$0.00
$0.43
Q3 25
$-0.02
$0.27
Q2 25
$-0.03
$0.25
Q1 25
$-0.04
$0.25
Q4 24
$-0.12
$0.11
Q3 24
$-0.06
$0.10
Q2 24
$0.00
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
PDLB
PDLB
Cash + ST InvestmentsLiquidity on hand
$307.8M
$126.2M
Total DebtLower is stronger
$596.1M
Stockholders' EquityBook value
$541.5M
Total Assets
$645.8M
$3.2B
Debt / EquityLower = less leverage
1.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
PDLB
PDLB
Q1 26
$307.8M
Q4 25
$302.6M
$126.2M
Q3 25
$286.6M
$146.6M
Q2 25
$298.7M
$126.6M
Q1 25
$281.8M
$129.9M
Q4 24
$294.2M
$139.8M
Q3 24
$305.7M
$155.8M
Q2 24
$306.7M
$103.2M
Total Debt
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
$596.1M
Q3 25
$521.1M
Q2 25
$536.1M
Q1 25
$521.1M
Q4 24
$596.1M
Q3 24
$580.4M
Q2 24
$680.4M
Stockholders' Equity
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
$459.3M
$541.5M
Q3 25
$458.9M
$529.8M
Q2 25
$464.9M
$521.1M
Q1 25
$473.7M
$513.9M
Q4 24
$486.2M
$505.5M
Q3 24
$531.4M
$504.6M
Q2 24
$551.9M
$497.7M
Total Assets
AMRN
AMRN
PDLB
PDLB
Q1 26
$645.8M
Q4 25
$670.8M
$3.2B
Q3 25
$659.8M
$3.2B
Q2 25
$670.1M
$3.2B
Q1 25
$655.7M
$3.1B
Q4 24
$685.3M
$3.0B
Q3 24
$750.6M
$3.0B
Q2 24
$799.9M
$2.8B
Debt / Equity
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
1.10×
Q3 25
0.98×
Q2 25
1.03×
Q1 25
1.01×
Q4 24
1.18×
Q3 24
1.15×
Q2 24
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
PDLB
PDLB
Operating Cash FlowLast quarter
$55.6M
Free Cash FlowOCF − Capex
$54.6M
FCF MarginFCF / Revenue
173.9%
Capex IntensityCapex / Revenue
3.1%
Cash ConversionOCF / Net Profit
5.48×
TTM Free Cash FlowTrailing 4 quarters
$74.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
$15.3M
$55.6M
Q3 25
$-12.7M
$1.4M
Q2 25
$16.6M
$6.2M
Q1 25
$-12.5M
$13.1M
Q4 24
$-13.3M
$7.2M
Q3 24
$-2.4M
$-14.6M
Q2 24
$-2.7M
$-2.6M
Free Cash Flow
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
$54.6M
Q3 25
$786.0K
Q2 25
$5.9M
Q1 25
$12.9M
Q4 24
$4.5M
Q3 24
$-15.0M
Q2 24
$-2.6M
FCF Margin
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
173.9%
Q3 25
2.9%
Q2 25
22.4%
Q1 25
52.6%
Q4 24
19.7%
Q3 24
-74.1%
Q2 24
-13.0%
Capex Intensity
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
3.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
11.9%
Q3 24
2.0%
Q2 24
0.3%
Cash Conversion
AMRN
AMRN
PDLB
PDLB
Q1 26
Q4 25
5.48×
Q3 25
0.21×
Q2 25
1.01×
Q1 25
2.20×
Q4 24
2.46×
Q3 24
-5.99×
Q2 24
-1.81×
-0.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

PDLB
PDLB

Segment breakdown not available.

Related Comparisons